Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

9.740 -0.250 (-2.50%)
Official Closing Price Updated: 4:15 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
4 Analysts Have This to Say About Viatris
Viatris (NASDAQ:VTRS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Want to Collect a High Dividend Every Month? Buy These 3 Stocks
Together, these stocks will ensure you're receiving a dividend each month of the year. 
Via The Motley Fool
Ocuphire Pharma Shares Jump After Global Licensing Pact For Nyxol Eye Drops
 
Via Benzinga
Why Viatris Stock Is Jumping Today
Investors are applauding a key step in Viatris' plans to return to growth. 
Via The Motley Fool
Why Viatris Shares Are Soaring Higher
Viatris Inc (NASDAQ: VTRS) shares are trading higher by 16.80% to $11.33 Monday morning after the company announced it will acquire Oyster Point Pharma. What Happened? 
Via Benzinga
Viatris' Mylan Recalls One Lot Of Octreotide Acetate Injection Due To Glass Particulates
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development 
Via Spotlight Growth
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge
 
Via Benzinga
IAA Stock Moves as Ritchie Bros Acquires Company in $7.3 Billion Deal
IAA (IAA) stock is moving on Monday thanks to a massive acquisition $7.3 billion deal with Ritchie Bros Auctioneers (RBA). 
Via InvestorPlace
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Viatris (VTRS) Stock Pops 17% on Acquisition News
One press release with numerous positive catalysts is prompting some VTRS stock traders to load up on the shares today. 
Via InvestorPlace
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
What Does Sunshine Biopharma's Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. 
Via Benzinga
Cramer On This Stock Up 138% Year-To-Date: 'Santa Can't Afford That Coal, It's Going Up Too Much'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Cano Health Inc (NYSE: CANO). 
Via Benzinga
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Recap: Viatris Q3 Earnings
Viatris (NASDAQ:VTRS) reported its Q3 earnings results on Monday, November 7, 2022 at 06:50 AM. Here's what investors need to know about the announcement. Earnings Viatris beat estimated earnings by... 
Via Benzinga
How To Attend Viatris Q3 2022 Earnings Conference Call
Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on November 7, 2022, to discuss Q3 2022 earnings results. How to Attend Viatris (VTRS) Conference Call Follow this link to access the... 
Via Benzinga
3 Feel-Good Ways to Lose Lots of Money in the Bear Market
All three are liable to happen when you lose your focus on investing for the long term. 
Via The Motley Fool
Recent Stock Purchase Update For October 2022
As you may know by now, I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. Let's take a look at what I've added to my portfolio... 
Via Talk Markets
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
3 Healthcare Stocks That Are Too Cheap to Ignore
They all offer attractive dividends, too. 
Via The Motley Fool
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
Procrastination could be problematic with these three bargain stocks. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 1076 companies hit new 52-week lows. 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.